KalVista Pharmaceuticals, Inc.
KALV
$13.31
$0.100.76%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -37.06% | -44.08% | -12.99% | 37.85% | 5.42% |
| Gross Profit | 37.06% | 44.08% | 12.99% | -37.85% | -5.42% |
| SG&A Expenses | 68.65% | 185.53% | 174.01% | 79.86% | 198.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.57% | 29.53% | 54.01% | 51.98% | 52.72% |
| Operating Income | -13.57% | -29.53% | -54.01% | -51.98% | -52.72% |
| Income Before Tax | -18.89% | -52.48% | -52.87% | -59.75% | -69.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.97% | -67.11% | -52.87% | -59.75% | -69.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.97% | -67.11% | -52.87% | -59.75% | -69.74% |
| EBIT | -13.57% | -29.53% | -54.01% | -51.98% | -52.72% |
| EBITDA | -13.54% | -29.65% | -54.27% | -52.22% | -52.94% |
| EPS Basic | 3.88% | -10.23% | -13.16% | -18.91% | -33.72% |
| Normalized Basic EPS | 2.05% | -0.32% | -12.47% | -18.37% | -34.60% |
| EPS Diluted | 3.88% | -10.23% | -13.16% | -18.91% | -33.72% |
| Normalized Diluted EPS | 2.05% | -0.32% | -12.47% | -18.37% | -34.60% |
| Average Basic Shares Outstanding | 21.69% | 51.59% | 35.09% | 34.34% | 26.93% |
| Average Diluted Shares Outstanding | 21.69% | 51.59% | 35.09% | 34.34% | 26.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |